胎儿生长受限预防和治疗干预随机对照试验的结局报告差异
该系统评价检索MEDLINE、EMBASE和Cochrane图书馆至2018年8月,纳入72项研究(68项试验),评估胎儿生长受限预防或治疗干预的结局报告差异。共识别238个结局,最常报告为出生体重(88.2%)、出生时孕周(72.1%)和小于胎龄儿(67.6%),仅27.9%报告新生儿发病率、17.6%报告干预不良反应。作者认为结局报告存在显著差异,建议开发核心结局集以提升未来研究的临床适用性。
要点
- 共纳入72项研究(68项试验),预防性试验44项、治疗性试验24项,平均Jadad评分3.07。
- 共识别238个结局,出生体重(88.2%)、出生时孕周(72.1%)和小于胎龄儿(67.6%)报告最多。
- 仅27.9%的研究报告新生儿发病率,仅17.6%的试验报告干预不良反应。
核心结论
- 胎儿生长受限预防和治疗干预的随机对照试验结局报告存在显著差异,作者认为开发核心结局集可增强未来研究的临床适用性。
研究设计与样本
- 系统评价,检索MEDLINE、EMBASE和Cochrane图书馆自建库至2018年8月,纳入72项研究(68项试验),其中预防性试验44项、治疗性试验24项,采用Jadad评分评估方法学质量。
主要发现
- 共识别238个结局,最常报告为出生体重(88.2%)、出生时孕周(72.1%)和小于胎龄儿(67.6%)。
- 仅27.9%的研究报告任何新生儿发病率指标,仅17.6%的试验报告干预不良反应。
- 所有研究的平均Jadad评分为3.07,仅9项研究获得5分。
关键数值与推荐
- 共识别238个结局,出生体重报告率88.2%、出生时孕周72.1%、小于胎龄儿67.6%、新生儿发病率27.9%、干预不良反应17.6%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Although fetal growth restriction (FGR) is well known to be associated with adverse outcomes for the mother and offspring, effective interventions for the management of FGR are yet to be established. Trials reporting interventions for the prevention and treatment of FGR may be limited by heterogeneity in the underlying pathophysiology. The aim of this study was to conduct a systematic review of outcomes reported in randomized controlled trials (RCTs) assessing interventions for the prevention or treatment of FGR, in order to identify and categorize the variation in outcome reporting. METHODS: MEDLINE, EMBASE and The Cochrane Library were searched from inception until August 2018 for RCTs investigating therapies for the prevention and treatment of FGR. Studies were assessed systematically and data on outcomes that were reported in the included studies were extracted and categorized. The methodological quality of the included studies was assessed using the Jadad score. RESULTS: The search identified 2609 citations, of which 153 were selected for full-text review and 72 studies (68 trials) were included in the final analysis. There were 44 trials relating to the prevention of FGR and 24 trials investigating interventions for the treatment of FGR. The mean Jadad score of all studies was 3.07, and only nine of them received a score of 5. We identified 238 outcomes across the included studies. The most commonly reported were birth weight (88.2%), gestational age at birth (72.1%) and small-for-gestational age (67.6%). Few studies reported on any measure of neonatal morbidity (27.9%), while adverse effects of the interventions were reported in only 17.6% of trials. CONCLUSIONS: There is significant variation in outcome reporting across RCTs of therapies for the prevention and treatment of FGR. The clinical applicability of future research would be enhanced by the development of a core outcome set for use in future trials. Copyright © 2018 ISUOG. Published by John Wiley & Sons Ltd.
引用
- Townsend R, Sileo F, Stocker L, et al. Variation in outcome reporting in randomized controlled trials of interventions for prevention and treatment of fetal growth restriction. Ultrasound Obstet Gynecol. 2019. PMID: 30523658. doi:10.1002/uog.20189
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。